Nilanjan Ghosh, MD, PhD, on New Avenues of CAR T Research in Lymphoma


The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.

“CAR T-cell research is branching into novel antigens, dual targets, allogeneic CAR Ts, and methods to reduce the time needed for an autologous product to be developed. As we see more follow up with this over the next year or few years, we will learn more about them. It's very exciting research.”

As more chimeric antigen receptor (CAR) T-cell therapies come to market, clinicians are beginning to see the long-term impact of these treatments in the clinic. Currently approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies include lisocabtagene maraleucel (Breyanzi), axicabtagene cliolecleucel (Yescarta), brexucabtagene autoleucel (Tecartus) and ciltacabtagene autoleucel (Carvykti).

Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute, is seeing first-hand the impact of these cell therapies in hematologic malignancies. He has experience with these therapies on the clinic side and treats patients with malignancies such as lymphomas.

CGTLive spoke to Ghosh to learn more about new avenues of research with CAR T-cell therapies and what new advances may come up in the next few years. He discussed a few programs of note, including Novartis’ YTB323, Allogene’s ALLO501A, LV20.19, dual-targeted CAR T-cell therapies, and CD30-targeted CAR T-cell therapies.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.